Stage 3: 410 Real Stories

410 stories match stage 3. 339 of them mention chemotherapy.

Stephanie, who was diagnosed with Stage III Colorectal CancerColorectal Cancer

Stephanie’s Stage 3 Colon Cancer Story

Patient Info: Stephanie, Female, Under 40 | Stage III

CT and PET imaging after treatment showed no active colon cancer. Her October 2023 scans were clear and her oncologist described the cancer as in remission; unchanged spots in the liver and lung continued to be monitored.

The Patient Story
OutcomeCancer-Free / Remission
Payton, who was diagnosed with Stage III Lung AdenocarcinomaLung Cancer

Stage III Lung Adenocarcinoma: Payton's Survivor Story

Patient Info: Payton Gibbs, Female, Under 40 | Stage III

As of August 2024, Payton described herself as cancer-free after lobectomy and 4 rounds of adjuvant chemotherapy.

The Patient Story
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage III Breast CancerBreast Cancer

Triple-negative breast cancer: partial response to TAC chemotherapy

Patient Info: Anonymized, Female, 70+ | Stage III

Biomarkers: Triple-negative breast cancer with EGFR positivity and high Ki-67; BRCA1 staining was positive by IHC.

After 1 cycle of TAC chemotherapy, the large ulcerated breast tumor shrank enough for surgery. Radical mastectomy with adjacent flap transfer achieved clear margins and no nodal metastatic cancer; she was recovering at home while awaiting planned postoperative AC-T chemotherapy.

PubMed Central
OutcomeCare Ongoing
A patient, who was diagnosed with Stage III Invasive Ductal CarcinomaBreast Cancer

Stage 3 infiltrating ductal carcinoma treated with radical mastectomy

Patient Info: Anonymized, Male, 50s | Stage III

Biomarkers: Breast cancer was ER/PR positive, HER2 negative

The patient recovered fully after right radical mastectomy and complete axillary dissection for Stage III male breast infiltrating ductal carcinoma; adjuvant therapy and recurrence follow-up were not reported in the extracted case text.

PubMed Central
OutcomeSurvivorship / Completed Treatment
A patient, who was diagnosed with Stage III Lung AdenocarcinomaLung Cancer

Stage IIIA ALK-positive lung adenocarcinoma: pathologic complete response to lorlatinib

Patient Info: Anonymized, Male, Under 40 | Stage III

Biomarkers: EML4-ALK fusion; ALK-positive; Napsin A-positive; cytokeratin-positive; TTF-1-positive

He remained disease-free 10 months after surgery while continuing planned adjuvant lorlatinib after neoadjuvant lorlatinib produced partial radiographic response and pathologic complete response.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage III Non-Small Cell Lung CancerLung Cancer

Stage 3 lung cancer: complete response to chemo and immunotherapy

Patient Info: Anonymized, Male, 70+ | Stage III

Biomarkers: Tumor markers were normal during mesorectal nodule workup; lung molecular biomarkers were not reported.

No radiologic NSCLC recurrence was detected during 16 months of follow-up after complete response to cisplatin/docetaxel chemoradiation plus 1 year of durvalumab; the suspicious mesorectal nodule proved to be a benign organized thrombus.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage III Non-Small Cell Lung CancerLung Cancer

Stage IIIA ALK-rearranged NSCLC: pathologic complete response to neoadjuvant brigatinib

Patient Info: Anonymized, Male, Under 40 | Stage III

Biomarkers: ALK gene rearrangement; CEA 8.49 ng/mL

He remained disease-free during 13 months of follow-up after neoadjuvant brigatinib reduced Stage IIIA ALK-rearranged NSCLC and curative-intent surgery showed pathologic complete response.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage III Non-Small Cell Lung CancerLung Cancer

Stage 3 EGFR-mutant lung cancer: osimertinib response to surgery

Patient Info: Anonymized, Female, 50s | Stage III

Biomarkers: EGFR exon 19 deletion; PD-L1 tumor proportion score <=1%

No recurrence or metastasis was reported after neoadjuvant osimertinib, R0 left upper lobectomy with mediastinal lymphadenectomy, and ongoing adjuvant osimertinib for Stage IIIA EGFR exon 19 deletion lung adenocarcinoma.

PubMed Central
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage III Non-Small Cell Lung CancerLung Cancer

Stage IIIA NSCLC: recurrence-free after surgery, adjuvant chemotherapy, and one atezolizumab dose

Patient Info: Anonymized, Female, 60s | Stage III

Biomarkers: PD-L1 expression 20% by 22C3 assay

She remained free of lung-cancer recurrence for more than 1 year after surgery and adjuvant cisplatin/vinorelbine; atezolizumab was stopped after 1 dose because of severe immune-related toxicities that improved with steroid and immunoglobulin treatment.

PubMed Central
OutcomeCancer-Free / NED
Liz, who was diagnosed with Stage III Invasive Lobular CarcinomaBreast Cancer

Stage III HR-Positive Invasive Lobular Carcinoma: Liz's Patient Story

Patient Info: Liz O'Riordan, Female, 40s | Stage III

Biomarkers: ER-positive; HER2-negative; PIK3CA mutation reported by patient

As of June 2024, Liz described Stage III ER-positive/HER2-negative mixed ductal and lobular breast cancer followed by 2 locoregional recurrences after mastectomy; no distant metastatic disease was described for her personal story.

YouTube — Dr Liz O'Riordan
OutcomeSetback / Progression
Andrea, who was diagnosed with Stage III Colorectal CancerColorectal Cancer

Stage III Colorectal Cancer: Andrea's Survivor Story

Patient Info: Andrea, Female, Under 40 | Stage III

As of May 2024, Andrea had completed radiation with continuous 5-FU, 8 intensive chemotherapy infusions, tumor surgery with temporary ileostomy, and ileostomy reversal; a liver-lesion scare was a false alarm and she was cancer-free.

The Patient Story
OutcomeCancer-Free / NED
Katrece, who was diagnosed with Stage III Inflammatory Breast CancerBreast Cancer

Stage III Inflammatory Breast Cancer: Katrece's Patient Story

Patient Info: Katrece Nolen, Female | Stage III

More than 10 years after her diagnosis, Katrece was taking medication intended to reduce recurrence risk and remained active in advocacy for people with inflammatory breast cancer.

AACR
OutcomeNot reported
Andrea, who was diagnosed with Stage III Colorectal CancerColorectal Cancer

Stage III colorectal cancer: remission after treatment

Patient Info: Andrea, Female, Under 40 | Stage III

As of May 2024, Andrea described being in remission since June 2022, with no cancer seen on follow-up scans and tumor DNA tests remaining negative during close 3-month surveillance.

The Patient Story
OutcomeCancer-Free / NED
A patient, who was diagnosed with Stage III Invasive Ductal CarcinomaBreast Cancer

Triple-negative breast cancer and ovarian cancer treated with chemotherapy and PARP inhibitor

Patient Info: Anonymized, Female, 40s | Stage III

Biomarkers: Germline pathogenic BRCA2 c.6468_6469del; breast tumor triple-negative

As of April 2024, 6-week follow-up after breast and nodal radiation was unremarkable, erythema had resolved, and no breast, chest wall, respiratory, or axillary abnormality was found; longer-term control was not reported.

PubMed Central
OutcomeCare Ongoing
Michael, who was diagnosed with Stage III Colorectal AdenocarcinomaColorectal Cancer

Stage III Colorectal Adenocarcinoma: Michael's Survivor Story

Patient Info: Michael Holtz, Male, 40s | Stage III

Michael reported that capecitabine with radiation, surgery, and FOLFOX worked for him; current surveillance findings and recurrence status were not provided.

Fight Colorectal Cancer
OutcomeSurvivorship / Completed Treatment